Few things that I noted in conference call
Take - 22.4% margin. 23% range by end of year. FY18 target is 24%
EA - 17% by end of Mar 2017
Debt - Indian debt 100 Cr. Will be closed using QIP
Term loan in US$ which is cheap. Can be paid by internal accruals. 8 mn long term. 20m short term.
Will maintain 20% payout dividend ratio.
NT asset mgmt
Take not a typical technology company. It needs domain expertise - Doctors, Bio technicians etc.
On the industry trend
Life sciences R&D spend is going up in US and Asia. Europe not bullish.
On why EA is cyclical?why first half of the year is soft?
Nov to March more clinical filings. So q3-q4 gathers momentum
Disclosure: Invested. This is not an investment recommendation.